Sepsis Therapeutics: A Global Strategic Business Report
San Jose, California (PRWEB) August 25, 2011
Sepsis, an uncontrolled immune response to injury or infections, is among the leading causes of mortality worldwide. The death toll from this condition is comparable to the mortality rates of diseases such as malaria, AIDS/HIV, pneumonia, tuberculosis, and other major forms of infections. In hospitals, sepsis is the major cause of death in non-coronary intensive care units. The lack of an early diagnostic test or effective treatment process enhances the risk associated with sepsis. An aging global population, rising incidence of sepsis among the elderly, and alarming rise of sepsis across other demographic groups is increasing the mortality rate and burdening healthcare resources. The growing use of interventional procedures, particularly among the elderly, is expected to enhance the need for sepsis management drugs. Another major factor contributing to the rising number of sepsis patients is the growing resistance to antibiotics. Despite the recent advancements in sepsis management and therapy, the mortality rate associated with severe sepsis remains high at about 30%. The need for drugs and therapies capable of effectively combating the condition presents enormous opportunities for pharmaceutical companies.
The United States accounts for a major share of global sales of sepsis drugs, as stated by the new market research report on Sepsis Therapeutics. Despite being one of the most virulent diseases, sepsis has attracted little commercial interest. A major factor being the high degree of complexity associated with the disease and its treatment, which in turn hampers the drug development process. Further, lack of efficacy has led companies to abandon or discontinue several late-stage clinical programs. Several trials pertaining to potential drugs have failed in their objective to improve patient outcome. As a result, severe sepsis continues to be an unmet clinical need with few options for treatment.
Eli Lilly’s Xigris (activated drotrecogin alfa) is the only FDA-approved drug for the treatment of sepsis. The product functions both as an anticoagulant and anti-inflammatory. Despite the enormous unmet medical needs of the sepsis segment, Xigris continues to struggle in the wake of regulatory actions and declining sales. Xigris’ use is limited due to the high risk of bleeding and the restricted indication for use in adult patients with significantly high risk of mortality. AstraZeneca’s CytoFab™ and Agennix’s Talactoferrin are among the major products that are currently under various stages of development.
Select players profiled in the report include Agennix AG, AstraZeneca Plc, Atox Bio Inc., CytoGenix Inc., Eli Lilly and Company, Endacea Inc., NexBio Inc., Medinox Inc., among others.
The research report titled “Sepsis Therapeutics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a strategic review of the industry, strategic corporate initiatives, and profiles of key market participants. The report provides annual sales estimates and projections for the following geographic markets – United States and Rest of World.
For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Sepsis_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/